AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 111 filers reported holding AKERO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 8.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,184,804 | -7.6% | 43,195 | -14.7% | 0.00% | 0.0% |
Q2 2023 | $2,363,402 | +120.0% | 50,619 | +80.3% | 0.00% | +100.0% |
Q1 2023 | $1,074,379 | -26.4% | 28,081 | +5.4% | 0.00% | -50.0% |
Q4 2022 | $1,459,817 | +231.0% | 26,639 | +105.3% | 0.00% | – |
Q3 2022 | $441,000 | +261.5% | 12,976 | +1.2% | 0.00% | – |
Q2 2022 | $122,000 | -23.3% | 12,827 | +14.8% | 0.00% | – |
Q1 2022 | $159,000 | -30.6% | 11,178 | +3.1% | 0.00% | – |
Q4 2021 | $229,000 | -66.4% | 10,838 | -64.5% | 0.00% | – |
Q3 2021 | $682,000 | +166.4% | 30,572 | +195.8% | 0.00% | – |
Q2 2021 | $256,000 | -21.5% | 10,337 | -7.8% | 0.00% | – |
Q1 2021 | $326,000 | -55.6% | 11,215 | -60.7% | 0.00% | – |
Q4 2020 | $735,000 | +141.8% | 28,503 | +188.5% | 0.00% | – |
Q3 2020 | $304,000 | – | 9,879 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |